Las Rozas de Madrid, Spain
Las Rozas de Madrid, Spain

Time filter

Source Type

Guerra-Perez N.,IRYCIS Hospital Ramon y Cajal | Guerra-Perez N.,Center for Biomedical Research | Ramos E.,IRYCIS Hospital Ramon y Cajal | Garcia-Hernandez M.,Aptus Biotech SL | And 4 more authors.
PLoS ONE | Year: 2015

Summary A poly (A)-binding protein from Leishmania infantum (LiPABP) has been recently cloned and characterized in our laboratory. Although this protein shows a very high homology with PABPs from other eukaryotic organisms including mammals and other parasites, exist divergences along the sequence that convert them in potential diagnostic markers and/or therapeutics targets. Aptamers are oligonucleotide ligands that are selected in vitro by their affinity and specificity for the target as a consequence of the particular tertiary structure that they are able to acquire depending on their sequence. Development of high-affinity molecules with the ability to recognize specifically Leishmania proteins is essential for the progress of this kind of study. Results We have selected a ssDNA aptamer population against a recombinant 6xHIS-LiPABP protein (rLiPABP) that is able to recognize the target with a low Kd. Cloning, sequencing and in silico analysis of the aptamers obtained from the population yielded three aptamers (ApPABP#3, ApPABP#7 and ApPABP#11) that significantly bound to PABP with higher affinity than the naïve population. These aptamers were analyzed by ELONA and slot blot to establish affinity and specificity for rLiPABP. Results demonstrated that the three aptamers have high affinity and specificity for the target and that they are able to detect an endogenous LiPABP (eLiPABP) protein amount corresponding to 2500 L. infantum promastigotes in a significant manner. The functional analysis of the aptamers also revealed that ApPABP#11 disrupts the binding of both Myc-LiPABP and eLiPABP to poly (A) in vitro. On the other hand, these aptamers are able to bind and purify LiPABP from complex mixes. Conclusion Results presented here demonstrate that aptamers represent new reagents for characterization of LiPABP and that they can affect LiPABP activity. At this respect, the use of these aptamers as therapeutic tool affecting the physiological role of PABP has to be analyzed. © 2015 Guerra-Pérez et al.This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


PubMed | Aptus Biotech SL, Autonomous University of Madrid and IRYCIS Hospital Ramon y Cajal
Type: Journal Article | Journal: PloS one | Year: 2015

A poly (A)-binding protein from Leishmania infantum (LiPABP) has been recently cloned and characterized in our laboratory. Although this protein shows a very high homology with PABPs from other eukaryotic organisms including mammals and other parasites, exist divergences along the sequence that convert them in potential diagnostic markers and/or therapeutics targets. Aptamers are oligonucleotide ligands that are selected in vitro by their affinity and specificity for the target as a consequence of the particular tertiary structure that they are able to acquire depending on their sequence. Development of high-affinity molecules with the ability to recognize specifically Leishmania proteins is essential for the progress of this kind of study.We have selected a ssDNA aptamer population against a recombinant 6xHIS-LiPABP protein (rLiPABP) that is able to recognize the target with a low Kd. Cloning, sequencing and in silico analysis of the aptamers obtained from the population yielded three aptamers (ApPABP#3, ApPABP#7 and ApPABP#11) that significantly bound to PABP with higher affinity than the nave population. These aptamers were analyzed by ELONA and slot blot to establish affinity and specificity for rLiPABP. Results demonstrated that the three aptamers have high affinity and specificity for the target and that they are able to detect an endogenous LiPABP (eLiPABP) protein amount corresponding to 2500 L. infantum promastigotes in a significant manner. The functional analysis of the aptamers also revealed that ApPABP#11 disrupts the binding of both Myc-LiPABP and eLiPABP to poly (A) in vitro. On the other hand, these aptamers are able to bind and purify LiPABP from complex mixes.Results presented here demonstrate that aptamers represent new reagents for characterization of LiPABP and that they can affect LiPABP activity. At this respect, the use of these aptamers as therapeutic tool affecting the physiological role of PABP has to be analyzed.


News Article | November 22, 2016
Site: www.newsmaker.com.au

According to Stratistics MRC, the Global Aptamers market is expected to grow from $109.23 million in 2015 to reach $346.14 million by 2022 with a CAGR of 17.9%. Huge R&D investments in bio-tech companies to develop applications in the field of diagnostics is the major factor propelling the market growth. In addition, high cost efficiency of aptamers, and technological developments are the key factors driving the market growth. However, strict regulations, ethical issues related to using aptamers, and lack of trained professional are the factors inhibiting the market growth.  Access the complete report at: http://www.strategymrc.com/report/aptamers-market Nucleic acid aptamers segment is witnessing a significant growth driven by increasing research and development activities and growing usage in diagnostic applications for the treatment of diseases such as autoimmune diseases, cancer and HIV/AIDS.  North America is anticipated to be the largest market for aptamers, whereas Asia Pacific is projected to grow at a faster pace. Favorable government initiatives and increased research and development activities in the U.S are propelling the market growth in North America region. Some of the key players in global aptamers market include Bioapter S.L., Base Pair Biotechnologies, Inc., Optech Biotech, Ophthotech Corporation, NOXXON Pharma AG, Neoventures Biotechnology Inc., CD Genomics, Aptagen, LLC, Am Biotechnologies, LLC, Aptus Biotech S.L., Aptamer Solutions Ltd., Aptamer Sciences Inc., Vivonics, Inc., Trilink Biotechnologies, Inc., Somalogic, Inc., and Regado Biosciences, Inc. Request for a sample at: http://www.strategymrc.com/report/aptamers-market Aptamer Types Covered: • Nucleic Acid Aptamers o DNA-Based o RNA-Based • Peptide Aptamers Applications Covered: • Diagnostics o Biomarker Detection and Discovery o Molecular Imaging • Therapeutics Development • Research and Development o Drug Discovery and Development o Targeted Drug Delivery • Other Applications o Biosensor o Food Safety Technologies Covered: • SELEX • Other Technologies End Users Covered: • Bio-Tech Companies • Academia • CRO's • Other End Users Regions Covered: • North America o US o Canada o Mexico • Europe o Germany o France o Italy o UK  o Spain      o Rest of Europe  • Asia Pacific o Japan o China o India o Australia o New Zealand o Rest of Asia Pacific • Rest of the World o Middle East o Brazil o Argentina o South Africa o Egypt What our report offers: - Market share assessments for the regional and country level segments - Market share analysis of the top industry players - Strategic recommendations for the new entrants - Market forecasts for a minimum of 7 years of all the mentioned segments, sub segments and the regional markets - Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations) - Strategic recommendations in key business segments based on the market estimations - Competitive landscaping mapping the key common trends - Company profiling with detailed strategies, financials, and recent developments - Supply chain trends mapping the latest technological advancements


Garcia-Recio E.M.,IRYCIS Hospital Ramon y Cajal | Pinto-Diez C.,IRYCIS Hospital Ramon y Cajal | Perez-Morgado M.I.,IRYCIS Hospital Ramon y Cajal | Garcia-Hernandez M.,Aptus Biotech SL | And 3 more authors.
Molecular Therapy - Nucleic Acids | Year: 2016

Elevated expression levels of eukaryotic initiation factor 4E (eIF4E) promote cancer development and progression. MAP kinase interacting kinases (MNKs) modulate the function of eIF4E through the phosphorylation that is necessary for oncogenic transformation. Therefore, pharmacologic MNK inhibitors may provide a nontoxic and effective anticancer strategy. MNK1b is a truncated isoform of MNK1a that is active in the absence of stimuli. Using in vitro selection, high-affinity DNA aptamers to MNK1b were selected from a library of ssDNA. Selection was monitored using the enzyme-linked oligonucleotide assay (ELONA), and the selected aptamer population was cloned and sequenced. Four groups of aptamers were identified, and the affinities of one representative for rMNK1b were determined using ELONA and quantitative polymerase chain reaction. Two aptamers, named apMNK2F and apMNK3R, had a lower Kd in the nmol/l range. The secondary structure of the selected aptamers was predicted using mFold, and the QGRS Mapper indicated the presence of potential G-quadruplex structures in both aptamers. The selected aptamers were highly specific against MNK1, showing higher affinity to MNK1b than to MNK1a. Interestingly, both aptamers were able to produce significant translation inhibition and prevent tumor cell proliferation and migration and colony formation in breast cancer cells. These results indicate that MNK1 aptamers have an attractive therapeutic potential.


Martin M.E.,Hospital Ramon y Cajal | Garcia-Hernandez M.,Aptus Biotech SL | Garcia-Recio E.M.,Hospital Ramon y Cajal | Gomez-Chacon G.F.,Aptus Biotech SL | And 2 more authors.
PLoS ONE | Year: 2013

Parasites of the genus Leishmania produce leishmaniasis which affects millions people around the world. Understanding the molecular characteristics of the parasite can increase the knowledge about the mechanisms underlying disease development and progression. Thus, the study of the molecular features of histones has been considered of particular interest because Leishmania does not condense the chromatin during mitosis and, consequently, a different role for these proteins in the biology of the parasite can be expected. Furthermore, the sequence divergences in the amino and in the carboxy-terminal domains of the kinetoplastid core histones convert them in potential diagnostic and/or therapeutics targets. Aptamers are oligonucleotide ligands that are selected in vitro by their affinity and specificity for the target as a consequence of the particular tertiary structure that they are able to acquire depending on their sequence. Development of high-affinity molecules with the ability to recognize specifically Leishmania histones is essential for the progress of this kind of study. Two aptamers which specifically recognize Leishmania infantum H2A histone were cloned from a previously obtained ssDNA enriched population. These aptamers were sequenced and subjected to an in silico analysis. ELONA, slot blot and Western blot were performed to establish aptamer affinity and specificity for LiH2A histone and ELONA assays using peptides corresponding to overlapped sequences of LiH2A were made mapping the aptamers:LiH2A interaction. As "proofs of concept", aptamers were used to determine the number of parasites in an ELONA platform and to purify LiH2A from complex mixtures. The aptamers showed different secondary structures among them; however, both of them were able to recognize the same peptides located in a side of the protein. In addition, we demonstrate that these aptamers are useful for LiH2A identification and also may be of potential application as diagnostic system and as a laboratory tool with purification purpose. © 2013 Martin et al.


PubMed | Instituto Ramon Y Cajal Of Investigacion Sanitaria Irycis Hospital Ramon Y Cajal and Aptus Biotech SL
Type: Review | Journal: Pharmaceuticals (Basel, Switzerland) | Year: 2016

Appropriate diagnosis is the key factor for treatment of viral diseases. Time is the most important factor in rapidly developing and epidemiologically dangerous diseases, such as influenza, Ebola and SARS. Chronic viral diseases such as HIV-1 or HCV are asymptomatic or oligosymptomatic and the therapeutic success mainly depends on early detection of the infective agent. Over the last years, aptamer technology has been used in a wide range of diagnostic and therapeutic applications and, concretely, several strategies are currently being explored using aptamers against virus proteins. From a diagnostics point of view, aptamers are being designed as a bio-recognition element in diagnostic systems to detect viral proteins either in the blood (serum or plasma) or into infected cells. Another potential use of aptamers is for therapeutics of viral infections, interfering in the interaction between the virus and the host using aptamers targeting host-cell matrix receptors, or attacking the virus intracellularly, targeting proteins implicated in the viral replication cycle. In this paper, we review how aptamers working against viral proteins are discovered, with a focus on recent advances that improve the aptamers properties as a real tool for viral infection detection and treatment.


PubMed | Aptus Biotech SL and IRYCIS Hospital Ramon y Cajal
Type: | Journal: Molecular therapy. Nucleic acids | Year: 2016

Elevated expression levels of eukaryotic initiation factor 4E (eIF4E) promote cancer development and progression. MAP kinase interacting kinases (MNKs) modulate the function of eIF4E through the phosphorylation that is necessary for oncogenic transformation. Therefore, pharmacologic MNK inhibitors may provide a nontoxic and effective anticancer strategy. MNK1b is a truncated isoform of MNK1a that is active in the absence of stimuli. Using in vitro selection, high-affinity DNA aptamers to MNK1b were selected from a library of ssDNA. Selection was monitored using the enzyme-linked oligonucleotide assay (ELONA), and the selected aptamer population was cloned and sequenced. Four groups of aptamers were identified, and the affinities of one representative for rMNK1b were determined using ELONA and quantitative polymerase chain reaction. Two aptamers, named apMNK2F and apMNK3R, had a lower Kd in the nmol/l range. The secondary structure of the selected aptamers was predicted using mFold, and the QGRS Mapper indicated the presence of potential G-quadruplex structures in both aptamers. The selected aptamers were highly specific against MNK1, showing higher affinity to MNK1b than to MNK1a. Interestingly, both aptamers were able to produce significant translation inhibition and prevent tumor cell proliferation and migration and colony formation in breast cancer cells. These results indicate that MNK1 aptamers have an attractive therapeutic potential.


Aptamers Market 2016- Aptus Biotech, NeoVentures Biotechnology, Aptamer Solutions, Base Pair Biotechnologies. A market study based on the  Aptamers market  across the globe, recently added to the repository of QY Market Research, is titled ‘Global Aptamers Market 2016’. The research report analyzes the historical as well as present performance of the global Aptamers market, and makes predictions on the future status of Aptamers market on the basis of this analysis. The report studies the market for Aptamers across the globe taking the existing industry chain, the import and export statistics in Aptamers market & dynamics of demand and supply of Aptamers into consideration. Aptamer Solutions Ltd. (U.K.) Aptus Biotech S.L. (Spain) Base Pair Biotechnologies, Inc. (U.S.) NeoVentures Biotechnology, Inc. (Canada) SomaLogic, Inc. (U.S.) TriLink BioTechnologies, Inc. (U.S.) Vivonics, Inc. (U.S.) The ' Aptamers 'research study covers each and every aspect of the Aptamers market globally, which starts from the definition of the Aptamers market and develops towards Aptamers market segmentations. Further, every segment of the Aptamers market is classified and analyzed on the basis of product types, application, and the end-use industries of the Aptamers market. The geographical segmentation of the Aptamers market has also been covered at length in this report. The competitive landscape of the global market for Aptamers is determined by evaluating the various market participants, production capacity, Aptamers market's production chain, and the revenue generated by each manufacturer in the Aptamers market worldwide. The global Aptamers market 2016 is also analyzed on the basis of product pricing, Aptamers production volume, data regarding demand and Aptamers supply, and the revenue garnered by the product. Various methodical tools such as investment returns, feasibility, and market attractiveness analysis has been used in the research to present a comprehensive study of the market for Aptamers across the globe.


News Article | November 3, 2016
Site: marketersmedia.com

— Huge R&D investments in bio-tech companies to develop applications in the field of diagnostics is the major factor propelling the market growth. In addition, high cost efficiency of aptamers, and technological developments are the key factors driving the market growth. However, strict regulations, ethical issues related to using aptamers, and lack of trained professional are the factors inhibiting the market growth. Nucleic acid aptamers segment is witnessing a significant growth driven by increasing research and development activities and growing usage in diagnostic applications for the treatment of diseases such as autoimmune diseases, cancer and HIV/AIDS. North America is anticipated to be the largest market for aptamers, whereas Asia Pacific is projected to grow at a faster pace. Favorable government initiatives and increased research and development activities in the U.S are propelling the market growth in North America region. Some of the key players in global aptamers market include Bioapter S.L., Base Pair Biotechnologies, Inc., Optech Biotech, Ophthotech Corporation, NOXXON Pharma AG, Neoventures Biotechnology Inc., CD Genomics, Aptagen, LLC, Am Biotechnologies, LLC, Aptus Biotech S.L., Aptamer Solutions Ltd., Aptamer Sciences Inc., Vivonics, Inc., Trilink Biotechnologies, Inc., Somalogic, Inc., and Regado Biosciences, Inc. Applications Covered: • Diagnostics o Biomarker Detection and Discovery o Molecular Imaging • Therapeutics Development • Research and Development o Drug Discovery and Development o Targeted Drug Delivery • Other Applications o Biosensor o Food Safety Regions Covered: • North America o US o Canada o Mexico • Europe o Germany o France o Italy o UK o Spain o Rest of Europe • Asia Pacific o Japan o China o India o Australia o New Zealand o Rest of Asia Pacific • Rest of the World o Middle East o Brazil o Argentina o South Africa o Egypt What our report offers: - Market share assessments for the regional and country level segments - Market share analysis of the top industry players - Strategic recommendations for the new entrants - Market forecasts for a minimum of 7 years of all the mentioned segments, sub segments and the regional markets - Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations) - Strategic recommendations in key business segments based on the market estimations - Competitive landscaping mapping the key common trends - Company profiling with detailed strategies, financials, and recent developments - Supply chain trends mapping the latest technological advancements About Stratistics MRC We offer wide spectrum of research and consulting services with in-depth knowledge of different industries. We are known for customized research services, consulting services and Full Time Equivalent (FTE) services in the research world. We explore the market trends and draw our insights with valid assessments and analytical views. We use advanced techniques and tools among the quantitative and qualitative methodologies to identify the market trends. Our research reports and publications are routed to help our clients to design their business models and enhance their business growth in the competitive market scenario. We have a strong team with hand-picked consultants including project managers, implementers, industry experts, researchers, research evaluators and analysts with years of experience in delivering the complex projects. For more information, please visit http://www.strategymrc.com/

Loading Aptus Biotech SL collaborators
Loading Aptus Biotech SL collaborators